Hautinfiltrate einer chronisch lymphatischen Leukämie getriggert durch topische Imiquimodtherapie

Hartmann, Julia; Enk, Alexander; Toberer, Ferdinand

doi:10.1111/ddg.13781

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly yes. Interestingly, Hartmann et al published the case of a patient with CLL who presented with cutaneous CLL‐infiltrates four weeks after this site had been treated with imiquimod 18 . The infiltrates consisted of monomorphous lymphocytes positive for CD5, CD20, and CD43.…”

Section: Discussionmentioning

confidence: 99%

Mucosal side effects in patients treated with topical imiquimod—A scoping review of the literature

Hammerl

Parlar

Navarini

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Imiquimod 5% is approved for topical treatment of actinic keratosis (AKs), superficial basal cell carcinoma and condylomata acuminata, the 3.75% formulation for the treatment of AKs and genital warts. Imiquimod has also been used off‐label in various other skin conditions (eg, Bowen's disease, lentigo maligna, vulvar intraepithelial neoplasia). As a toll‐like receptor 7/8 (TLR7/8) agonist imiquimod induces a local inflammatory response by increased production of cytokines, co‐stimulatory molecules, activation of Nk‐cells and antigen‐specific T‐cells. In addition to imiquimod‐associated adverse effects at non‐application sites such as fever, vertigo or myalgia there have been anecdotal reports of distant inflammatory mucosal reactions—a side effect not declared in the medicinal product information. In this scoping review we collected a total of seven cases of patients with lesions of the oral mucosa and lips and summarized pathophysiological hypotheses to explain this type of side effect. The review is complemented with an illustrated report of a 87‐year‐old female patient of ours suffering from chronic lymphocytic leukemia (CLL) who developed severe oral mucosal and labial reactions following application of imiquimod 3.75% for treatment of AKs. She denied accidental transfer of imiquimod and was tested negative for herpes simplex virus (PCR) and bacteria (culture) from lesional swabs.

show abstract

Section: Discussionmentioning

confidence: 99%